heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-02. Anything still debated is marked as such rather than presented as settled.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
| Property | Value | Notes |
|---|---|---|
| Primary research models | Rodent studies | Largest share of published data |
| Reported markers | BDNF and NGF expression | Measured mainly in animal tissue |
| Common administration | Intranasal | Matches the registered formulation |
| Blood residence time | Minutes | Rapid enzymatic degradation |
| Evidence quality | Small trials, limited replication | Noted repeatedly in reviews |
纯度评估以反相高效液相色谱为主，通过主峰面积百分比给出粗略结果，再配合电喷雾质谱核对分子量。氨基酸分析可验证组成比例，手性色谱或毛细管电泳用于检查残基构型。常见杂质包括缺失序列的短肽、氧化产物与二聚体。由于多数市售品不附带完整检验报告，独立第三方检测常被用来核实标称值。
从分子层面看，Semax 是线性七肽，没有二硫键、糖基或脂链修饰，N 端为游离氨基，C 端为游离羧基。分子含组氨酸与谷氨酸侧链，因此在水和甲醇等极性溶剂中溶解良好，在非极性溶剂中溶解有限。计算分子量约为 814 Da，与其质子化离子的质荷比吻合，可用于质谱确认。
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
However, all three co-authors of the bill issued a statement that instead, the bill "[narrowed] existing broad presidential authority to take over telecommunications networks". In August 2010, the U.S. for the first time warned publicly about the Chinese military's use of civilian computer experts in clandestine cyber attacks aimed at American companies and government agencies. The Pentagon also pointed to an alleged China-based computer spying network dubbed GhostNet which was revealed in a 2009 research report. On 6 October 2011, it was announced that Creech AFB's drone and Predator fleet's command and control data stream had been keylogged, resisting all attempts to reverse the exploit, for the past two weeks. The Air Force issued a statement that the virus had "posed no threat to our operational mission". On 21 November 2011, it was widely reported in the U.S. media that a hacker had destroyed a water pump at the Curran-Gardner Township Public Water District in Illinois. However, it later turned out that this information was not only false, but had been inappropriately leaked from the Illinois Statewide Terrorism and Intelligence Center. In June 2012 the New York Times reported that president Obama had ordered the cyber attack on Iranian nuclear enrichment facilities. In August 2012, USA Today reported that the US conducted cyberattacks for tactical advantage in Afghanistan.
The Gravity Gun (also known as the Zero-point Energy Field Manipulator) is a fictional device from the first-person shooter video game Half-Life 2 and its subsequent episodes wielded by the protagonist, Gordon Freeman. Designed for handling hazardous materials, but mostly used for heavy lifting by the anti-Combine resistance, it is capable of picking up and throwing numerous types of objects, including extremely heavy ones, at a high rate of speed, and is used as both a weapon and an obstacle-clearing tool. Due to the novel game mechanics it allows for, it has become known as one of the most iconic video game weapons, and inspired similar physics manipulation tools in subsequent games.
== Epidemiology == The prevalence of primary polycythemia (polycythemia vera) was estimated to be approximately 44–57 per 100,000 individuals in the United States. Secondary polycythemia is considered to be more common, but its exact prevalence is unknown. In one study using the NHANES dataset, the prevalence of unexplained erythrocytosis is 35.1 per 100,000, and was higher among males and among individuals between ages 50–59 and 60–69.
== Hormonal regulation == Glucoregulation is the maintenance of steady levels of glucose in the body. Hormones released from the pancreas regulate the overall metabolism of glucose. Insulin and glucagon are the primary hormones involved in maintaining a steady level of glucose in the blood, and the release of each is controlled by the amount of nutrients currently available. The amount of insulin released in the blood and sensitivity of the cells to the insulin both determine the amount of glucose that cells break down. Increased levels of glucagon activates the enzymes that catalyze glycogenolysis, and inhibits the enzymes that catalyze glycogenesis. Conversely, glycogenesis is enhanced and glycogenolysis inhibited when there are high levels of insulin in the blood. The level of circulatory glucose (known informally as "blood sugar"), as well as the detection of nutrients in the Duodenum is the most important factor determining the amount of glucagon or insulin produced. The release of glucagon is precipitated by low levels of blood glucose, whereas high levels of blood glucose stimulates cells to produce insulin. Because the level of circulatory glucose is largely determined by the intake of dietary carbohydrates, diet controls major aspects of metabolism via insulin. In humans, insulin is made by beta cells in the pancreas, fat is stored in adipose tissue cells, and glycogen is both stored and released as needed by liver cells. Regardless of insulin levels, no glucose is released to the blood from internal glycogen stores from muscle cells.
The CAP has three main parts. First, the European Agricultural Guarantee Fund distributes 'direct payments', which are 70.9% of the CAP budget. The Direct Payments Regulation 2013 gives payments to an 'active farmer' that carries out agricultural activity, grazing or cultivation, does not operate airports, rail, waterworks, real estate, sport or recreation grounds, and has the land at their disposal. The farm must have at least 1 hectare and receive €100 for each, though member states can set higher thresholds (e.g. 5 hectares and €200). If payments reach over €150,000 there is a 5% reduction per hectare for each hectare. This favours large farm corporations, and the largest 1% typically receive around 10 to 15% of all subsidies in member states. As conditions of receiving subsidies, farms can be required to keep land in good condition, for public, animal, and plant health, and maintain environment standards. For minimal biodiversity, farmers must have over two crops if they have 10 hectares, not farm at least 5% of lintensively (an 'ecological focus area' over 15 hectares, and have three crops over 30 hectares. Environmentally sensitive grasslands, as designated by the Habitats Directive 1992 and the Wild Birds Directive 2009, should not be more turned into more than 5% agricultural area. The second main part, also carried out by the EAGF, is 'market measures'. Under the Agricultural Products Regulation 2013 certain crops and meat are eligible for purchase by member state authorities, to be 'stored by them until disposed of', with extra aid for storage.
Sources: en.wikipedia.org
Square pyramidal for five-coordination Capped octahedral or capped trigonal prismatic for seven-coordination Dodecahedral or bicapped trigonal prismatic for eight-coordination Capped square antiprismatic for nine-coordination To distinguish between the alternative coordinations for five-coordinated complexes, the τ geometry index was invented by Addison et al. This index depends on angles by the coordination center and changes between 0 for the square pyramidal to 1 for trigonal bipyramidal structures, allowing to classify the cases in between. This system was later extended to four-coordinated complexes by Houser et al. and also Okuniewski et al. In systems with low d electron count, due to special electronic effects such as (second-order) Jahn–Teller stabilization, certain geometries (in which the coordination atoms do not follow a points-on-a-sphere pattern) are stabilized relative to the other possibilities, e.g. for some compounds the trigonal prismatic geometry is stabilized relative to octahedral structures for six-coordination.
=== Mixed === In mixed inhibition the inhibitor may bind to the enzyme whether or not the substrate has already bound. Hence mixed inhibition is a combination of competitive and noncompetitive inhibition. Furthermore, the affinity of the inhibitor for the free enzyme and the enzyme-substrate complex may differ. By increasing concentrations of substrate [S], this type of inhibition can be reduced (due to the competitive contribution), but not entirely overcome (due to the noncompetitive component). Although it is possible for mixed-type inhibitors to bind in the active site, this type of inhibition generally results from an allosteric effect where the inhibitor binds to a different site on an enzyme. Inhibitor binding to this allosteric site changes the conformation (that is, the tertiary structure or three-dimensional shape) of the enzyme so that the affinity of the substrate for the active site is reduced. These four types of inhibition can also be distinguished by the effect of increasing the substrate concentration [S] on the degree of inhibition caused by a given amount of inhibitor. For competitive inhibition the degree of inhibition is reduced by increasing [S], for noncompetitive inhibition the degree of inhibition is unchanged, and for uncompetitive (also called anticompetitive) inhibition the degree of inhibition increases with [S].
== Occurrence == The compound is produced by human pathogens such as Aspergillus fumigatus, and also by species of Trichoderma and Penicillium. Gliotoxin has also been reported from yeasts of the genus Candida, but results from other studies have cast doubt on the production of this metabolite by Candida fungi. Gliotoxin is not produced by nonpathogenic A. fischeri although A.fischeri contains a gene cluster that is homologous to the gliotoxin gene cluster found in the pathogenic A. fumigatus. Gliotoxin contributes to the pathogenicity of opportunistic fungi by suppressing the immune system response of its host. Gliotoxin additionally possesses fungicidal and bacteriostatic properties, which indicates that it likely plays an important self defense role against bacteria and other fungi for the fungi that produce gliotoxin. Exposure of A. fumigatus to exogenous gliotoxin resulted in aberrant protein expression, especially in those strains that lacked the self-protection protein GliT. There is additional evidence for differential gliotoxin sensitivities amongst fungi including Aspergillus flavus, Fusarium graminearum, and Aspergillus oryzae.
=== Post-Sinestro Corps War === Boodikka becomes a member of the Alpha Lanterns. The Lanterns being enhanced with Manhunter technology, effectively making them cyborgs. Boodikka later falls under the mental control of Cyborg Superman. As she attacks Kyle Rayner, Soranik Natu, and John Stewart, Green Lantern member Hannu ambushes and severely injures her. This temporarily frees Boodikka from Cyborg Superman's control; she instructs the other Lanterns to recharge the battery with the energy she has absorbed. Her fellow Lanterns repair her enough for her to fight, and she joins in the attack on Cyborg Superman's base. During the battle, Cyborg Superman's body is destroyed and his consciousness attempts to take control of Boodikka's body. Boodikka's consciousness fights back, defeating him. On her return to Oa, Boodikka is made a member of the Lantern Honor Guard.
== Model organism in genetics == D. melanogaster remains one of the most studied organisms in biological research, particularly in genetics and developmental biology. It is also employed in studies of environmental mutagenesis.
Sources: en.wikipedia.org
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.
The compound is registered as a medicine in Russia, so clinical work has concentrated there. Trials elsewhere are few and generally small. This geographic concentration is a recognized limitation in evidence reviews.
Some fraction may reach the central nervous system through olfactory pathways, and this is often cited as the rationale for the nasal route. The size of that fraction in humans is not well quantified. Blood concentrations after nasal dosing are low, which complicates measurement.
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.